LABELS · da94c24a-0943-4544-8286-467d7c073c34

Prednisolone Sodium Phosphate

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2024-09-23
Captured: 2026-09-09T23:38:02.384588+00:00
Current indication reconciliation: Not reconciled

Indications and usage: exact source text

INDICATIONS AND USAGE Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti- PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); Trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents).

Full extracted label fields

application numbers

NDA019157

boxed warning exact

brand names

Prednisolone Sodium Phosphate

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=833ba492-8823-43b4-9a91-8b28d94a740b

generic names

PREDNISOLONE SODIUM PHOSPHATE

da94c24a-0943-4544-8286-467d7c073c34

indications and usage exact

INDICATIONS AND USAGE Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti- PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); Trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents).

indications and usage tables exact

is original packager

true

manufacturer names

Seton Pharmaceuticals, LLC

matched search terms

cancer
lymphomas
leukemia

package ndcs

13925-166-04

product ndcs

13925-166

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

ORAL

rxcuis

312614

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00700.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · indication intro context

application numbers

NDA019157

brand names

Prednisolone Sodium Phosphate

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement
incomplete_colon_led_indication_intro

clinical review status

pending

content role

indication_intro_context

context span

end: 310
end exclusive: true
exact text: INDICATIONS AND USAGE Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergi
label id: da94c24a-0943-4544-8286-467d7c073c34
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start: 0

current approval status

not_reconciled

duplicate text group

dup-bd18f09919a925aacfba

extraction review status

automated_candidate_pending_source_review

generic names

PREDNISOLONE SODIUM PHOSPHATE

ind-span-8a628c31996268ae1e93

label id

da94c24a-0943-4544-8286-467d7c073c34

positive predicate support span

end: 78
end exclusive: true
exact text: is indicated
label id: da94c24a-0943-4544-8286-467d7c073c34
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start: 66

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 110
end exclusive: true
exact text: INDICATIONS AND USAGE Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1.
label id: da94c24a-0943-4544-8286-467d7c073c34
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22da94c24a-0943-4544-8286-467d7c073c34%22

spl effective date

2024-09-23

spl set id

833ba492-8823-43b4-9a91-8b28d94a740b

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 2 · unclassified context

application numbers

NDA019157

brand names

Prednisolone Sodium Phosphate

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 620
end exclusive: true
exact text: INDICATIONS AND USAGE Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce di
label id: da94c24a-0943-4544-8286-467d7c073c34
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start: 0

current approval status

not_reconciled

duplicate text group

dup-3913d20c43093da95eb5

extraction review status

automated_candidate_pending_source_review

generic names

PREDNISOLONE SODIUM PHOSPHATE

ind-span-0baea9fd37828627f752

label id

da94c24a-0943-4544-8286-467d7c073c34

positive predicate support span

Source null

qualifier mentions

context exact
intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial aller
kind
age
polarity
not_inferred
span
end
248
end exclusive
true
exact text
adult
label id
da94c24a-0943-4544-8286-467d7c073c34
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start
243
context exact
e to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis;
kind
age
polarity
not_inferred
span
end
262
end exclusive
true
exact text
pediatric
label id
da94c24a-0943-4544-8286-467d7c073c34
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start
253

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 420
end exclusive: true
exact text: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2.
label id: da94c24a-0943-4544-8286-467d7c073c34
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start: 111

source url

https://api.fda.gov/drug/label.json?search=id%3A%22da94c24a-0943-4544-8286-467d7c073c34%22

spl effective date

2024-09-23

spl set id

833ba492-8823-43b4-9a91-8b28d94a740b

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 3 · unclassified context

application numbers

NDA019157

brand names

Prednisolone Sodium Phosphate

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 790
end exclusive: true
exact text: entional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, w
label id: da94c24a-0943-4544-8286-467d7c073c34
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start: 221

current approval status

not_reconciled

duplicate text group

dup-ceb38f860395ce07dac2

extraction review status

automated_candidate_pending_source_review

generic names

PREDNISOLONE SODIUM PHOSPHATE

ind-span-421b9e4ed45af206f903

label id

da94c24a-0943-4544-8286-467d7c073c34

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 590
end exclusive: true
exact text: Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3.
label id: da94c24a-0943-4544-8286-467d7c073c34
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start: 421

source url

https://api.fda.gov/drug/label.json?search=id%3A%22da94c24a-0943-4544-8286-467d7c073c34%22

spl effective date

2024-09-23

spl set id

833ba492-8823-43b4-9a91-8b28d94a740b

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · positive indication candidate

application numbers

NDA019157

brand names

Prednisolone Sodium Phosphate

classification reasons

inherited_predicate_from_same_label_section_requires_review
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1007
end exclusive: true
exact text: ypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where appl
label id: da94c24a-0943-4544-8286-467d7c073c34
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start: 391

current approval status

not_reconciled

duplicate text group

dup-a3ec8976fa909950f0d6

extraction review status

automated_candidate_pending_source_review

generic names

PREDNISOLONE SODIUM PHOSPHATE

ind-span-e6a16c873dc05291a0f1

label id

da94c24a-0943-4544-8286-467d7c073c34

positive predicate support span

end: 78
end exclusive: true
exact text: is indicated
label id: da94c24a-0943-4544-8286-467d7c073c34
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start: 66

qualifier mentions

context exact
uresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric popula
kind
age
polarity
not_inferred
span
end
686
end exclusive
true
exact text
adults
label id
da94c24a-0943-4544-8286-467d7c073c34
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start
680
context exact
ephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndro
kind
age
polarity
not_inferred
span
end
725
end exclusive
true
exact text
adults
label id
da94c24a-0943-4544-8286-467d7c073c34
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start
719
context exact
ndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without ur
kind
age
polarity
not_inferred
span
end
739
end exclusive
true
exact text
pediatric
label id
da94c24a-0943-4544-8286-467d7c073c34
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start
730

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 807
end exclusive: true
exact text: Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4.
label id: da94c24a-0943-4544-8286-467d7c073c34
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start: 591

source url

https://api.fda.gov/drug/label.json?search=id%3A%22da94c24a-0943-4544-8286-467d7c073c34%22

spl effective date

2024-09-23

spl set id

833ba492-8823-43b4-9a91-8b28d94a740b

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 5 · unclassified context

application numbers

NDA019157

brand names

Prednisolone Sodium Phosphate

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1390
end exclusive: true
exact text: To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults;
label id: da94c24a-0943-4544-8286-467d7c073c34
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start: 608

current approval status

not_reconciled

duplicate text group

dup-959c6753c8caebf6c4c7

extraction review status

automated_candidate_pending_source_review

generic names

PREDNISOLONE SODIUM PHOSPHATE

ind-span-a0f469986ac73eaf2e24

label id

da94c24a-0943-4544-8286-467d7c073c34

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1190
end exclusive: true
exact text: Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5.
label id: da94c24a-0943-4544-8286-467d7c073c34
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start: 808

source url

https://api.fda.gov/drug/label.json?search=id%3A%22da94c24a-0943-4544-8286-467d7c073c34%22

spl effective date

2024-09-23

spl set id

833ba492-8823-43b4-9a91-8b28d94a740b

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 6 · unclassified context

application numbers

NDA019157

brand names

Prednisolone Sodium Phosphate

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1521
end exclusive: true
exact text: coids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anem
label id: da94c24a-0943-4544-8286-467d7c073c34
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start: 991

current approval status

not_reconciled

duplicate text group

dup-a92463c7c48c21d41c94

extraction review status

automated_candidate_pending_source_review

generic names

PREDNISOLONE SODIUM PHOSPHATE

ind-span-13ad98bb56b1a2f0ae25

label id

da94c24a-0943-4544-8286-467d7c073c34

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1321
end exclusive: true
exact text: Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6.
label id: da94c24a-0943-4544-8286-467d7c073c34
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start: 1191

source url

https://api.fda.gov/drug/label.json?search=id%3A%22da94c24a-0943-4544-8286-467d7c073c34%22

spl effective date

2024-09-23

spl set id

833ba492-8823-43b4-9a91-8b28d94a740b

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 7 · unclassified context

application numbers

NDA019157

brand names

Prednisolone Sodium Phosphate

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1727
end exclusive: true
exact text: hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis an
label id: da94c24a-0943-4544-8286-467d7c073c34
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start: 1122

current approval status

not_reconciled

duplicate text group

dup-b8324bc3cc71ff3f20ea

extraction review status

automated_candidate_pending_source_review

generic names

PREDNISOLONE SODIUM PHOSPHATE

ind-span-accd6844996a560727b9

label id

da94c24a-0943-4544-8286-467d7c073c34

positive predicate support span

Source null

qualifier mentions

context exact
ematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (au
kind
age
polarity
not_inferred
span
end
1389
end exclusive
true
exact text
adults
label id
da94c24a-0943-4544-8286-467d7c073c34
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start
1383

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1527
end exclusive: true
exact text: Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7.
label id: da94c24a-0943-4544-8286-467d7c073c34
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start: 1322

source url

https://api.fda.gov/drug/label.json?search=id%3A%22da94c24a-0943-4544-8286-467d7c073c34%22

spl effective date

2024-09-23

spl set id

833ba492-8823-43b4-9a91-8b28d94a740b

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · unclassified context

application numbers

NDA019157

brand names

Prednisolone Sodium Phosphate

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1835
end exclusive: true
exact text: logic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic op
label id: da94c24a-0943-4544-8286-467d7c073c34
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start: 1328

current approval status

not_reconciled

duplicate text group

dup-479722f4551d79794b6c

extraction review status

automated_candidate_pending_source_review

generic names

PREDNISOLONE SODIUM PHOSPHATE

ind-span-9e4d3390eab2c05bd37a

label id

da94c24a-0943-4544-8286-467d7c073c34

positive predicate support span

Source null

qualifier mentions

context exact
the treatment of acute leukemia and aggressive lymphomas in adults and children. 8.
kind
age
polarity
not_inferred
span
end
1618
end exclusive
true
exact text
adults
label id
da94c24a-0943-4544-8286-467d7c073c34
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start
1612
context exact
nt of acute leukemia and aggressive lymphomas in adults and children. 8.
kind
age
polarity
not_inferred
span
end
1631
end exclusive
true
exact text
children
label id
da94c24a-0943-4544-8286-467d7c073c34
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start
1623

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1635
end exclusive: true
exact text: Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8.
label id: da94c24a-0943-4544-8286-467d7c073c34
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start: 1528

source url

https://api.fda.gov/drug/label.json?search=id%3A%22da94c24a-0943-4544-8286-467d7c073c34%22

spl effective date

2024-09-23

spl set id

833ba492-8823-43b4-9a91-8b28d94a740b

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 9 · unclassified context

application numbers

NDA019157

brand names

Prednisolone Sodium Phosphate

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1896
end exclusive: true
exact text: acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; i
label id: da94c24a-0943-4544-8286-467d7c073c34
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start: 1436

current approval status

not_reconciled

duplicate text group

dup-9e6811c89ea483309435

extraction review status

automated_candidate_pending_source_review

generic names

PREDNISOLONE SODIUM PHOSPHATE

ind-span-144a14730a0535824bdc

label id

da94c24a-0943-4544-8286-467d7c073c34

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1696
end exclusive: true
exact text: Nervous System Acute exacerbations of multiple sclerosis. 9.
label id: da94c24a-0943-4544-8286-467d7c073c34
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start: 1636

source url

https://api.fda.gov/drug/label.json?search=id%3A%22da94c24a-0943-4544-8286-467d7c073c34%22

spl effective date

2024-09-23

spl set id

833ba492-8823-43b4-9a91-8b28d94a740b

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 10 · unclassified context

application numbers

NDA019157

brand names

Prednisolone Sodium Phosphate

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2048
end exclusive: true
exact text: a; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemothera
label id: da94c24a-0943-4544-8286-467d7c073c34
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start: 1497

current approval status

not_reconciled

duplicate text group

dup-cf9279e6e9d8b06c0987

extraction review status

automated_candidate_pending_source_review

generic names

PREDNISOLONE SODIUM PHOSPHATE

ind-span-25d83e602839555027d9

label id

da94c24a-0943-4544-8286-467d7c073c34

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1848
end exclusive: true
exact text: Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10.
label id: da94c24a-0943-4544-8286-467d7c073c34
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start: 1697

source url

https://api.fda.gov/drug/label.json?search=id%3A%22da94c24a-0943-4544-8286-467d7c073c34%22

spl effective date

2024-09-23

spl set id

833ba492-8823-43b4-9a91-8b28d94a740b

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 11 · unclassified context

application numbers

NDA019157

brand names

Prednisolone Sodium Phosphate

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2631
end exclusive: true
exact text: m Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti- PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia.
label id: da94c24a-0943-4544-8286-467d7c073c34
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start: 1649

current approval status

not_reconciled

duplicate text group

dup-0c560c6e66991c172028

extraction review status

automated_candidate_pending_source_review

generic names

PREDNISOLONE SODIUM PHOSPHATE

ind-span-26c32b49bff192e3e452

label id

da94c24a-0943-4544-8286-467d7c073c34

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 2431
end exclusive: true
exact text: Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti- PCP antibiotics.
label id: da94c24a-0943-4544-8286-467d7c073c34
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start: 1849

source url

https://api.fda.gov/drug/label.json?search=id%3A%22da94c24a-0943-4544-8286-467d7c073c34%22

spl effective date

2024-09-23

spl set id

833ba492-8823-43b4-9a91-8b28d94a740b

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 12 · unclassified context

application numbers

NDA019157

brand names

Prednisolone Sodium Phosphate

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2835
end exclusive: true
exact text: ive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti- PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile r
label id: da94c24a-0943-4544-8286-467d7c073c34
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start: 2232

current approval status

not_reconciled

duplicate text group

dup-4f648d1e173eb8d443a8

extraction review status

automated_candidate_pending_source_review

generic names

PREDNISOLONE SODIUM PHOSPHATE

ind-span-e9c60a67337017276715

label id

da94c24a-0943-4544-8286-467d7c073c34

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 2635
end exclusive: true
exact text: Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11.
label id: da94c24a-0943-4544-8286-467d7c073c34
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start: 2432

source url

https://api.fda.gov/drug/label.json?search=id%3A%22da94c24a-0943-4544-8286-467d7c073c34%22

spl effective date

2024-09-23

spl set id

833ba492-8823-43b4-9a91-8b28d94a740b

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 13 · unclassified context

application numbers

NDA019157

brand names

Prednisolone Sodium Phosphate

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 3237
end exclusive: true
exact text: ies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellan
label id: da94c24a-0943-4544-8286-467d7c073c34
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start: 2436

current approval status

not_reconciled

duplicate text group

dup-38d120e023ea3ba38e28

extraction review status

automated_candidate_pending_source_review

generic names

PREDNISOLONE SODIUM PHOSPHATE

ind-span-05eeca8438e89cfeade8

label id

da94c24a-0943-4544-8286-467d7c073c34

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 3037
end exclusive: true
exact text: Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis.
label id: da94c24a-0943-4544-8286-467d7c073c34
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start: 2636

source url

https://api.fda.gov/drug/label.json?search=id%3A%22da94c24a-0943-4544-8286-467d7c073c34%22

spl effective date

2024-09-23

spl set id

833ba492-8823-43b4-9a91-8b28d94a740b

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 14 · unclassified context

application numbers

NDA019157

brand names

Prednisolone Sodium Phosphate

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 3427
end exclusive: true
exact text: matoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pe
label id: da94c24a-0943-4544-8286-467d7c073c34
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start: 2838

current approval status

not_reconciled

duplicate text group

dup-499b83ace91e2a7445ed

extraction review status

automated_candidate_pending_source_review

generic names

PREDNISOLONE SODIUM PHOSPHATE

ind-span-cb1319abf7e9ab4e4066

label id

da94c24a-0943-4544-8286-467d7c073c34

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 3227
end exclusive: true
exact text: For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychondritis, and certain cases of vasculitis. 12.
label id: da94c24a-0943-4544-8286-467d7c073c34
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start: 3038

source url

https://api.fda.gov/drug/label.json?search=id%3A%22da94c24a-0943-4544-8286-467d7c073c34%22

spl effective date

2024-09-23

spl set id

833ba492-8823-43b4-9a91-8b28d94a740b

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 15 · unclassified context

application numbers

NDA019157

brand names

Prednisolone Sodium Phosphate

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 3686
end exclusive: true
exact text: ndylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); Trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents).
label id: da94c24a-0943-4544-8286-467d7c073c34
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start: 3028

current approval status

not_reconciled

duplicate text group

dup-41a5b989288028e9bf95

extraction review status

automated_candidate_pending_source_review

generic names

PREDNISOLONE SODIUM PHOSPHATE

ind-span-701bf72ca1e1d9afb1a9

label id

da94c24a-0943-4544-8286-467d7c073c34

positive predicate support span

Source null

qualifier mentions

context exact
ardial involvement; acute or chronic solid organ rejection (with or without other agents).
kind
regimen
polarity
not_inferred
span
end
3685
end exclusive
true
exact text
with or without other agents)
label id
da94c24a-0943-4544-8286-467d7c073c34
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start
3656

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 3686
end exclusive: true
exact text: Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); Trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents).
label id: da94c24a-0943-4544-8286-467d7c073c34
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 0ba9cf6c258e9d981b18ed1283fc86f0ab6c9253d01f735d29c57a4303dfdef2
start: 3228

source url

https://api.fda.gov/drug/label.json?search=id%3A%22da94c24a-0943-4544-8286-467d7c073c34%22

spl effective date

2024-09-23

spl set id

833ba492-8823-43b4-9a91-8b28d94a740b

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Preserved source evidence · Not medical advice